» Articles » PMID: 22350508

STAT3 Silencing Enhances the Efficacy of the HSV.tk Suicide Gene in Gastrointestinal Cancer Therapy

Overview
Specialty Oncology
Date 2012 Feb 22
PMID 22350508
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Aberrant activation of Signal Transducer and Activator of Transcription 3 (STAT3) signaling has been shown to be associated with uncontrolled cell proliferation and suppression of host-immune surveillance. Conversely, silencing STAT3 can have the dual effects of inhibiting cancer cell proliferation and inducing anti-tumor immune responses. Here, we report on the effects of STAT3 silencing on suicide gene therapy with thymidine kinase (tk). STAT3 silencing by siRNA inhibited the proliferation of AGS human gastric cancer cells through G1 cell cycle arrest, decreased levels of immune-suppressive cytokines, and increased levels of immune-activating cytokines. CT26 mouse colon adenocarcinoma cells, in which STAT3 expression was knocked-down by a STAT3 shRNA-containing lentivirus, grew more slowly in syngenic model Balb/c mice than control CT26 cells. Moreover, we found that STAT3 silencing augmented the efficacy of suicide gene therapy in CT26 cell xenografted mice. When we administrated adenoviruses harboring the herpes simplex virus thymidine kinase gene (Ad5.CMV.HSV.tk) into STAT3-silenced CT26 cell tumors, extensive apoptosis was observed and there was a significant reduction in the size of CT26 cell tumors. STAT3 silencing also enhanced the recruitment and cytotoxic activity of CD3(+)CD8(+) T-cells, and changed the cytokine expression pattern of CT26 cell tumors, reflecting augmentation of anti-cancer immune responses. We conclude that combining suicide gene therapy with STAT3 silencing can result in enhanced anti-cancer effects.

Citing Articles

Therapeutic potential of gene therapy for gastrointestinal diseases: Advancements and future perspectives.

Yue N, Xu H, Xu J, Zhu M, Zhang Y, Tian C Mol Ther Oncolytics. 2023; 30:193-215.

PMID: 37663132 PMC: 10471515. DOI: 10.1016/j.omto.2023.08.007.


A Brief Introduction to Current Cancer Gene Therapy.

Kobelt D, Pahle J, Walther W Methods Mol Biol. 2022; 2521:1-21.

PMID: 35732990 DOI: 10.1007/978-1-0716-2441-8_1.


Neural differentiation of glioblastoma cell lines via a herpes simplex virus thymidine kinase/ganciclovir system driven by a glial fibrillary acidic protein promoter.

Luo E, Liao M, Chien C PLoS One. 2021; 16(8):e0253008.

PMID: 34370752 PMC: 8351974. DOI: 10.1371/journal.pone.0253008.


Crosstalk between WNT and STAT3 is mediated by galectin-3 in tumor progression.

Kim S, Kang H, Kim K, Kim H, Zetterberg F, Park Y Gastric Cancer. 2021; 24(5):1050-1062.

PMID: 33834359 PMC: 9907361. DOI: 10.1007/s10120-021-01186-5.


Glial TIM-3 Modulates Immune Responses in the Brain Tumor Microenvironment.

Kim H, Chang C, Yoon H, Kim K, Koh H, Kim S Cancer Res. 2020; 80(9):1833-1845.

PMID: 32094297 PMC: 8188274. DOI: 10.1158/0008-5472.CAN-19-2834.


References
1.
Brantley E, Benveniste E . Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res. 2008; 6(5):675-84. PMC: 3886801. DOI: 10.1158/1541-7786.MCR-07-2180. View

2.
Niu G, Heller R, Coppola D, Jaroszeski M, Dalton W, Jove R . Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 1999; 59(20):5059-63. View

3.
Lewis H, Winter A, Murphy T, Tripathi S, Pandey V, Barton B . STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5' and 3' ends. Mol Cancer Ther. 2008; 7(6):1543-50. PMC: 2561307. DOI: 10.1158/1535-7163.MCT-08-0154. View

4.
Kortylewski M, Yu H . Stat3 as a potential target for cancer immunotherapy. J Immunother. 2007; 30(2):131-9. DOI: 10.1097/01.cji.0000211327.76266.65. View

5.
Lau C, Yang Z, Lam S, Lam C, Ngai P, Tam K . Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. Cancer Biol Ther. 2007; 6(12):1900-7. DOI: 10.4161/cbt.6.12.4970. View